The research paper “Microtransplantation: Treatment of acute myeloid leukemia after remission” was published in the American Journal of Clinical Oncology, which was highly evaluated by international experts and described microtransplantation as “a new model for separating the anti-tumor effects of grafts and graft-versus-host disease. “. It is understood that the incidence of leukemia among young and middle-aged people is about 70%. At present, the domestic treatment of middle-aged and young people with acute myeloid leukemia in remission has been using traditional methods such as chemotherapy or hematopoietic stem cell transplantation, with a cure rate of less than 40% with chemotherapy and a cure rate of up to about 70% with transplantation, but the prerequisite for such transplantation is the need to find a perfectly matched donor, and because it is quite difficult to find a perfectly matched donor, there are very few lucky people who can do such transplantation, and the transplantation causes Serious infections and related complications after transplantation are up to 70% or more. Since 2003, Ai has led a team that has treated 101 young and middle-aged patients in remission from acute myeloid leukemia with microtransplantation, achieving unprecedented success. Compared with traditional hematopoietic stem cell transplantation, “microtransplantation” has strong anti-leukemic effects, fast hematopoietic recovery, safety and simplicity, no transplantation-related complications, and is not limited by the patient’s age and type, from children to elderly people over 80 years old can tolerate microtransplantation, regardless of family members or unrelated unmatched persons. Both family members and unrelated individuals can be used as microtransplant donors.